- LOGIN
- MemberShip
- 2025-12-24 21:46:20
- Company
- LG Chem Life Science achieves new quarterly sales record
- by Kim, Jin-Gu Aug 25, 2022 05:52am
- LG Chem’s Life Science company, which is in charge of the company’s pharmaceutical business, has broken its quarterly sales record in the second quarter of this year. Its flagship products - the Zemiglo series and growth hormone - had shown strong sales performance in Korea and abroad, rising nearly 20% in one year. According to the Financial Supervisory Service on the 24th, LG Chem’s Life Science sector recorded ₩205.2 billion in sales in Q2 this year. This is a 17.8% increase from the ₩174.2 billion made in Q2 last year. The cumulative sales in 1H this year were ₩408 billion. If the company maintains the current growth rate, it may record sales of nearly ₩1 trillion by the end of the year. The company has continued stable growth despite the prolonged COVID-19 crisis. Compared to Q2 2019 (₩152.3 billion) before the COVID-19 crisis, this is a 34.8% increase made in three years. This strong growth is interpreted to be the result of the strong performance shown by the company’s flagship product, “Zemiglo” series, the growth hormone “Eutrophin,” and hyaluronic acid injection for arthritis, “Synovian inj.” According to LG Chem, combined sales of the DPP-4 inhibitor type diabetes treatment “Zemiglo (gemigliptin),” its metformin combo “Zemimet,” and rosuvastatin combo “Zemiro,” recorded ₩32.6 billion in Q2 this year. The series recorded a 3% external growth compared to the ₩31.5 billion in Q2 last year and maintained its lead among DPP-4 inhibitor class diabetes treatments in Korea. In the same period, its domestic market share increased from 21.1% to 22.5%. In the case of Eutropin, another flagship product, its market share increased by 1%p from 41.0% to 42.0% in the The flagship products performed well in both the domestic and overseas markets. LG Chem Life Science’s exports increased 17.3% from the same period last year from ₩65.3 billion to ₩76.5 billion in Q2 this year. Domestic market sales increased 18.1% from ₩109 billion to ₩128.7 billion during the same period. However, the operating profits of the Life Science company in Q2 decreased 16.6% from ₩29.1 billion to ₩24.2 billion. LG Chem explained that profitability had decreased somewhat due to the rise of R&D expenses in line with progress made in the company’s clinical trials. LG Chem is conducting various clinical trials in Korea and abroad. In Korea, the company received approval for the Phase III clinical trial protocol of its precocious puberty treatment candidate “GPP001” in June. When development is completed, it is expected to create further synergy with the company’s existing growth hormone Eutropin. The company had also completed a Phase 3 clinical trial of the Zemiglo+metformin+dapagliflozin combination. In June, the combination was approved under the name of Zemidapa. Dapagliflozin is an SGLT-2 inhibitor class diabetes treatment, and if development is completed, Zemidapa is expected to become the company’s fourth Zemiglo series drug. The company is also developing new drugs for hereditary obesity and gout abroad. Among them, the company applied for a Phase III clinical trial for its new gout drug candidate “tigulixostat” to the US Food and Drug Administration (FDA) on August 1st. Also, the company is participating in the development of the immuno-oncology drug ‘CUE-102’ with its partner, Cue Biopharma. LG Chem owns the exclusive right to develop and market CUE-102 in 11 Asian countries including Korea, China, and Japan. LG Chem explained, “We plan to further expand R&D investment to develop global new drugs. In particular, we will focus on oncology which has high growth potential, and diabetes and metabolic diseases where we own extensive R&D experience.”
- Company
- Celltrion Applies to Europe for IND to designate Yuflyma
- by Aug 24, 2022 05:55am
- Celltrion announced on the 23rd that it has applied to European regulators for IND to designate Humira biosimilar Yuflyma (CT-17) as an interchangeable similar. If it is designated as an interchangeable similar, it can be prescribed by replacing the original at a pharmacy without intervention by MD. Celltrion recently submitted IND to the U.S. Food and Drug Administration (FDA) to secure a mutual exchange between Yuflyma and Humira. European clinical trials are conducted on 366 Plaque psoriasis patients in many countries, including Estonia and Poland. It plans to compare and verify pharmacokinetics, efficacy, and safety between the multiple cross-medication group between Yuflyma and Humira and the Humira maintenance medication group. Celltrion previously confirmed the efficacy, pharmacokinetics, and safety results similar to Humira through Global Phase 3 clinical trials of Yuflyma in patients with rheumatoid arthritis. Based on the clinical results, Yuflyma obtained permission to sell all indications held by Humira, such as RA, IBD, and PS, from EMA in February 2021 and is in progress. In the U.S., it has completed a patent agreement in the U.S. with its developer AbbVie so that it can start selling on July 1st next year. Celltrion expects FDA approval to sell Yuflyma within this year. When sales of Yuflyma begin in the U.S., it is expected that the advantages of high-concentration formulation, whether to secure interchangeable similarity status, and clinical results on various indications will serve as important competitiveness. Yuflyma is the first high-concentration Humira biosimilar to obtain permission from EMA, characterized by halving drug administration compared to low concentrations and removing citrate that can cause pain. An official from Celltrion said, "We believe that if Yuflyma secures its interchangeable biosimilar status through interchangeable clinical trials, it will greatly help expand its market share by strengthening its competitiveness." "High-quality bio at reasonable prices for global markets, including in Korea, while making every effort to prepare for clinical and licensing, and we will do our best to proceed with the supply of medicines."
- Company
- Omega-3 prescription market doubles in 3 Years
- by Kim, Jin-Gu Aug 23, 2022 06:03am
- KuhnilIt is expected that generic companies will join and fierce competition is expected. The market for Omega-3 is rapidly expanding. The performance of outpatient prescriptions in the first half of the year has more than doubled in three years. The prescription performance of Omega-3 and Statins has increased significantly. It is predicted that competition in this market will become fiercer in the future, centering on the omega-3 and Statin complex. According to UBIST, a pharmaceutical market research firm on the 17th, the size of outpatient prescriptions in the Omega-3 Rx market in the first half of this year is 72 billion won. Compared to the first half of 2019, it has expanded 2.1 times. This market is growing rapidly around 2020. Based on the quarterly prescription amount, it was below 20 billion won until the third quarter of 2019, but it surpassed 20 billion won in the fourth quarter and exceeded 30 billion won in the second quarter of 2021. In the second quarter of this year, it recorded 36.8 billion won, looking at the quarterly prescription amount of 40 billion won. While the Omega-3 single system has steadily expanded its influence, the Omega-3 and statin complex has joined in earnest, driving the market expansion. In fact, the prescription amount of omega-3 and statin composites in the first half of 2019 was only 2.4 billion won, but it increased 5.9 times in three years to 14.3 billion won this year. In July 2017, Kuhnil was approved for Rosumega as the first omega 3+ Rosuvastatin complex. Rosumega paid 600 million won in prescription that year, and increased to 4.1 billion won the following year. After recording 6.7 billion won in 2019, it has become a large item that pays about 10 billion won in prescriptions since 2020. With Rosumega on the market, other generic companies have joined the competition. In December 2020, Jeil, Yuyu, Boryeung, Kyung Dong, Korea Prime, and Futecs were granted generic of the Omega 3·Rosuvastatin complex. These products are manufactured by Kuhnil. Last year, United joined the new competition. Instead of commissioning production to Kuhnil, United challenged Kuhnil head-on through patent raids. United, which won the patent dispute, released Atmeg Combigel Soft Cap in the second quarter of last year as an Omega 3+ Atorvastatin compound. Atmeg Combigel is rapidly expanding its prescription performance with its release. The prescription amount, which was 1.2 billion won in the second quarter of last year, increased seven times to 8.3 billion won in the second quarter of this year. United plans to expand its performance to 20 billion won a year. It is expected to have more intense competition in the future, centering on the Omega-3 and Statin complex. Kuhnil was licensed for combination generics such as Atmeg Combigel, signaling competition. Along with Kuhnil, Daehannupharm, Dongkoo Bio, Hutecs, and Penmix are expected to enter the market. Kuhnil plans to produce their products on consignment. United plan to face Atmeg Combigel with new dosages. In addition to the existing Atorvastatin 10mg + Omega-3 1,000mg product, United has recently received approval for Atorvastatin 5mg + Omega-3 1000mg product. On top of that, it plans to release additional medicines with the same ingredients through its affiliated company Korea Biochem.
- Company
- Abilify 1mg can be prescribed at tertiary hospitals
- by Eo, Yun-Ho Aug 22, 2022 05:53am
- A new 1mg strength formulation of ‘Abilify’ can now be prescribed at general hospitals According to industry sources, Korea Otsuka Pharmaceutical's antipsychotic ‘Abilify (aripiprazole)’ has passed the drug committees (DCs) of major hospitals in Korea, including the Seoul National University Hospital, Seoul Asan Medical Center, and Sinchon Severance Hospital. The company has been working to make prompt entry into the market after receiving reimbursement approval for its new strength in March this year. The 2mg, 5mg, 10mg, and 15mg strengths of Abilify have already been approved in the past. The introduction of the 1mg strength is the first change made in the product lineup in 6 years since the company received approval for ‘Abilify Maintena inj.’ In 2015. When narrowing the product line to Abilify tablets alone, this is the first change made in 13 years since 2008 when the 2mg tablet formulation was approved. Although a 1mg strength for Abilify did not exist in the past, prescriptions of the 1mg dose have been frequently made by splitting the 2mg strength tablet. The 1mg dose was used for dose-sensitive first-time patients with neuropsychiatric disorders etc. Whether Abilify may be able to secure its sales in the market that is being challenged by generics by introducing the low-strength formulation remains to be seen. According to the market research institution IQVIA, Korea Otsuka Pharmaceutical's Abilify series makes the most sales among all schizophrenia treatments in Korea. Its 3 products - Abilify tab, Abilify OD tab, and Abilify Maintena inj – had raised ₩50.9 billion in sales in 2020. With the same product line, the company made ₩27.4 billion in the first half of the year last year.
- Company
- Strong performance of overseas subsidiaries of companies
- by Kim, Jin-Gu Aug 22, 2022 05:52am
- Starting from the left, "Beijing Hanmi", "YANGZHOU ILYANG PHARM", "GC China"Daewoong Pharmaceutical's Southeast Asian subsidiary doubled in a year. Major overseas subsidiaries of pharmaceutical bio companies showed strong sales in the first half of last year. Most of the local subsidiaries in China and Southeast Asia showed an increase in sales compared to the same period last year. Beijing Hanmi, Celltrion AP (Asia-Pacific), and Celltrion USA set new sales records based on half-year sales. ◆ Beijing Hanmi records half-year sales According to the Financial Supervisory Service on the 20th, the combined sales of 22 Chinese local subsidiaries of 10 Korean pharmaceutical companies in the first half of the year were 314.8 billion won. It increased 14% compared to 275.4 billion won during the same period last year. Net profit increased 28% from 38.5 billion won in the first half of last year to 49.1 billion won in the first half of this year. Beijing Hanmi broke the previous half-year sales record by making 173.3 billion won in sales in the first half of the year. It increased 30% compared to 132.9 billion won in sales in the first half of last year. Half-year sales of Beijing Hanmi recorded around 120 billion won before COVID-19. In the first half of 2020, when COVID-19 was rampant in China, it plunged to 92.8 billion won. However, after recovering to 110.7 billion won in the second half of 2020, 132.9 billion won in the first half of last year, 155.8 billion won in the second half of this year, and 173.3 billion won in the first half of this year. Beijing Hanmi expanded its syrup factory last year. The operation rate of this plant has been maintained at 100% this year. An official from the U.S. in Beijing explained, "As a result of timely expansion of facilities and supplying products in line with the rapid increase in demand for respiratory patients and cold medicines in China, we achieved solid performance until the first and second quarters." Most of the other Chinese subsidiaries have also grown by a large margin. In the case of Chong Kun Dang, sales at Chong Kun Dang Health in Qingdao more than tripled from 1.1 billion won to 6.7 billion won. Guangdong Pharmaceutical's total sales in the first half of the year were 20.1 billion won, up 24% from the same period last year. Daewoong Pharmaceutical has four subsidiaries in China, including Sacheon Daewoong Biotechnology Limited, Liaoning Daewoong Pharmaceutical Limited, and Beijing Daewoong Pharmaceutical and Technology Limited. The combined sales of the four corporations increased 39% from 8.8 billion won to 12.3 billion won in a year. YANGZHOU ILYANG PHARM·TONGHUA ILYANG HEALTH PRODUCTS of Ilyang Pharmaceutical recorded 71.2 billion won in sales in the first half of the year. It increased by 5% compared to 67.7 billion won in the first half of last year. Among major Chinese subsidiaries, sales of GC Pharma's subsidiaries declined. Total sales of GC China and GC China Pharm fell 34% year-on-year to 29.8 billion won. ◆ Celltrion and Takeda products in earnest in the Asia-Pacific region, Diagnostic kits are booming in the U.S Local subsidiaries in Southeast Asia also performed well in the first half of the year. Particularly noticeable is Celltrion's Celltrion Asia Pacific PTE located in Singapore. It recorded 75 billion won in sales in the first half of this year. It nearly tripled from 25.2 billion won in the first half of last year. Net profit also shifted from a deficit of 6.8 billion won to a surplus of 9.7 billion won. Analysts say that the sale of 18 products acquired from Takeda Pharmaceutical has begun in earnest. Celltrion Pharmaceutical is in charge of sales in Korea, and Celltrion Asia Pacific PTE is in charge of sales in the remaining eight countries, including Thailand, Taiwan, Hong Kong, Macau, the Philippines, Singapore, Malaysia, and Australia. In the case of Daewoong Pharmaceutical, the total sales of five local subsidiaries located in Thailand, Indonesia, and the Philippines more than doubled from 8.4 billion won to 17.2 billion won. In the case of Chong Kun Dang, sales of local subsidiaries in Indonesia increased 2.2 times from 2.1 billion won to 4.7 billion won in a year. In addition, in the North American market, Celltrion USA made strides by increasing its sales nearly 16 times in a year. Celltrion USA's sales in the first half of this year increased from 9.4 billion won last year to 150.4 billion won in the first half of this year. Celltrion USA's sales expansion is attributed to strong sales of COVID-19 diagnostic kits. Celltrion is jointly developing and selling antibody diagnostic kits, antigen rapid diagnostic kits, antigen home test diagnostic kits, and neutralization antibody diagnostic kits with Humasis. Among them, antigen rapid diagnostic kits and antigen home test diagnostic kits have been supplied to the U.S. in earnest since late last year through Celltrion USA.
- Company
- Avastin biosimilar Vegzelma has obtained a European license
- by Kim, Jin-Gu Aug 22, 2022 05:52am
- Celltrion announced on the 19th that Vegzelma (CT-P16) developed with Avastin biosimilar has obtained a sales license from EC on the 18th (local time). According to Celltrion, Vegzelma received an EMA approval recommendation in June. Within two months after that, it received permission to sell full labels approved by Avastin, including metastatic direct bowel cancer and non-small cell lung cancer. Celltrion's strategy is to quickly settle Vegzelma in the market with cost competitiveness by mobilizing all of its own drug development and production capabilities. Celltrion has also completed a global patent agreement with the original drug developer before obtaining Vegzelma's permission, and plans to release it in Europe through Celltrion Healthcare within this year. Vegzelma is the third anticancer antibody biosimilar developed by Celltrion after blood cancer treatment Truxima and breast cancer and stomach cancer treatment Herzuma. Celltrion expects Vegzelma's sales license in Europe to further strengthen its anti-cancer drug portfolio. Celltrion is revealing the possibility of Vegzelma's permission in the U.S. and Korean markets following Europe. Celltrion also applied for Vegzelma's sales license to the Ministry of Food and Drug Safety and the U.S. Food and Drug Administration (FDA) at the end of last year, and expects approval within the year. According to IQVIA, a global pharmaceutical market research firm, the global Bevacizumab market in 2021 is $6.413 billion, of which the European market accounts for $1.614 billion and the U.S. market accounts for $2.62 billion. A Celltrion official said, "With Vegzelma's permission to sell in Europe, Celltrion has secured its third anticancer antibody biosimilar." He said, "We will do our best to help Vegzelma settle in the European biosimilar market early and proceed with the remaining global licensing process without a hitch."
- Company
- Ibrance safety is OK even in male breast cancer patients
- by Eo, Yun-Ho Aug 19, 2022 05:53am
- Breast cancer treatment Ibrance has added safety-related product information in male patients. The Ministry of Food and Drug Safety recently added a phrase that male patients also showed consistent safety profiles with women in post-marketing experience through updating the permits of CDK4/6 inhibitor Ibrance of Pfizer Korea. The measure was based on the results of post-marketing surveys and electronic health records in the United States, and the U.S. FDA expanded its indication to prescribe Ibrance to male patients based on the data in 2019. Male breast cancer is a rare disease that accounts for about 1% of all breast cancers, and most of the patients' mammary tumors are expressed in hormone receptors and are generally treated with endocrine therapy, and Ibrance combined therapy is possible for progressive cancer. But, Ibrance has not secured an indication for male breast cancer in Korea. Meanwhile, Ibrance recently reaffirmed its effectiveness, including the Overall Survival, through a large-scale Real World study. The study, published in the European Society for Medical Oncology Breast Caner 2022, retrospectively analyzed the data of 2888 actual patients prescribed Ibrance combination therapy and Aromatase inhibitor monotherapy. As a result, OS median of Ibrance was 53.4 months, and Aromatase inhibitor alone was 40.4 months. The risk of death in Ibrance combination therapy was 33% lower.
- Company
- US FDA approves Samsung Bioepis' high conc Humira biosimilar
- by Kim, Jin-Gu Aug 19, 2022 05:53am
- On the 18th, Samsung Bioepis announced that the U.S. Food and Drug Administration (FDA) approved the high-concentration formulation of its Humira biosimilar, ‘Hadlima 100mg/mL’ on the 15th (local time). The company plans to market the high-concentration Hadlima in the US market in July next year through its US marketing partner, Organon. Hadlima is used for the treatment of rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, and plaque psoriasis. To improve patient convenience, the formulation will be offered to patients in a prefilled syringe (PFS) or autoinjector. The approval of the citrate-free, high-concentration Hadlima was based on clinical data from a clinical study that compared the pharmacokinetics, safety, tolerability, and immunogenicity of two formulations of Hadlima (100 mg/mL vs 50 mg/mL) in healthy volunteers. The low-concentration formulation (50 mg/mL) of Hadlima was previously approved by the FDA in July 2019. More than 5 million prescriptions of Hadlima had been made under various brand names since 2018. Byoungin Jung, VP and Team Leader of Regulatory Affairs at Samsung Bioepis, said, “With the FDA approval, we are now able to expand our treatment options to both the low- and high-concentration versions of Hadlima in the US. By leveraging our R&D expertise, manufacture, and supply chain management capabilities, we will continue our efforts to provide quality drugs to patients around the globe.”
- Company
- Indication of Norvatis Beovu's DME was expanded
- by Aug 19, 2022 05:52am
- Novartis Korea announced on the 17th that Beovu, an Age-related macular degeneration treatment, has added diabetic macular edema (DME). Beovu is a treatment that inhibits neonatal vascular expression and retinal effusion leakage in combination with VEGF-A. The Beovu dose for DME treatment is administered once every 6 weeks, 6 mg (0.05 mL) for the first 5 times, and once every 12 weeks thereafter. Patients with disease activity can be administered once every eight weeks. The administration interval is determined based on disease activity evaluated on vision and/or anatomical criteria. This permission was based on the results of 2 phase 3 clinical trials, KESTREL and KITE, which directly compared the efficacy and safety of the existing treatment, Aflibercept. The clinical trial was conducted on 926 patients with type 1 or type 2 diabetes (566 KESTREL and 360 KITE) aged 18 or older with impaired vision due to diabetic macular edema. In the Beovu medication group, loading dose was administered 5 times every 6 weeks, then administered every 12 weeks, and patients with confirmed disease activity were administered every 8 weeks. The control group was administered 5 times every 4 weeks with loading dos according to the drug's permission and then administered every 8 weeks. At the first year (52 weeks), the median was administered 7 times in the Beovu medication group and 9 times in the control group. The researchers said that existing anti-VEGF treatments that treat DME were usually administered monthly when administering loading dose, making it difficult to improve the patient's treatment burden and resulting symptoms, and based on the results of this study, Blucizumab-dbll will be a new treatment option to reduce the treatment burden for diabetic macular edema. DME is a disease that causes swelling in the macula by increasing vascular endothelial growth factors and proliferating new blood vessels as exudates flow from damaged microvascular vessels due to the inability to control high blood sugar. According to a paper published in 2011, DME is a major disease that causes blindness in adults in developed countries, with 12% of type 1 diabetes patients and 28% of type 2 diabetes patients being affected. Cho Yeon-jin, executive director of Novartis Korea's ophthalmology division, said, "We are pleased to expand treatment options to patients suffering from vision damage following Lucentis with the expansion of indications for the treatment of diabetic macular edema." Executive Director Cho Yeon-jin explained, "Novatis will continue to have leadership in the field of eye disease treatments and make efforts to introduce treatments with efficacy and safety to clinical sites."
- Company
- Why is the exp. date of the Sanofi flu vaccine short?
- by Aug 18, 2022 01:06pm
- With domestic and foreign pharmaceutical companies starting to distribute flu (influenza) vaccines, the expiration date of the Sanofi vaccine is about three months shorter than that of other products. This means that the Sanofi vaccine must be discarded in April, when Korea is still considered to be a flu epidemic period, so it cannot be used. Sanofi explained that it is the best way to speed up the introduction of Korean products. According to the pharmaceutical industry on the 17th, domestic and foreign pharmaceutical companies such as Sanofi, GC Pharma, Boryung Biopharma, Ilyang Pharmaceutical, and Korea Vaccine have started supplying vaccines in preparation for the 2022-2023 seasonal flu epidemic. According to the current status of the seasonal flu vaccine lot release for domestic use released by the Ministry of Food and Drug Safety, a total of 9.32 million people were approved for shipment from July 18 to the 12th of this month. Among them, the expiration date of Sanofi's flu vaccine Vaxigrip is about seven months later, until March 31, 2023, which is particularly shorter than other vaccines. Sanofi received Lot releases for each lot of Vaxigrip on August 1, 2, 4, and 9, which were valid for the same period as March 31 next year. The flu vaccine is usually valid for one year. The validity period of other flu vaccines approved for shipment at the same time is around June-July next year, about a year later. For example, GC Pharma's GC FLU , which received a Lot release on August 1, has an expiration date of June 12, 2023, and Korea Vacine's Kovax-Flu validity period, which was approved on the same day, is June 23, 2023. On August 10, Boryung Bio Pharma's Boryung Flu, which was released on August 10, is specified to expire on July 5, 2023. Ilyang Pharmaceutical Terrestrial Pfs, which received a lot release on July 19, ahead of Sanofi, also has an expiration date of June 14, 2023. This means that the expiration date of Vaxigrip is about three months shorter than that of other flu vaccines, so Vaxigrip must be discarded in April next year, when the flu vaccine is in vogue. In Korea, the flu epidemic is expected from October to April of the following year. The government's national flu vaccination project is also in line with this. The expiration date is not a problem when receiving national shipping approval, but vaccine manufacturers generally distribute vaccines that can be received until the end of the business period. This is because if the expiration date ends within the epidemic period, products that need to be discarded can be inoculated to consumers, and common sense believes that it is inappropriate to supply products that need to be discarded within the business period. Some raise suspicions that the reason why Sanofi supplied the flu vaccine so early is because of the expiration date. Originally, Sanofi distributed the flu vaccine in Korea from September to October every year with GSK. In the case of imported finished products, unlike domestic manufactured vaccines, it takes longer to finish production at foreign factories and enter Korea through a certification process. However, this year, Sanofi began supplying vaccines at the same time as domestic manufacturers. Previously, the expiration date was longer than this, so there was no big difficulty in supplying from September to October, but this year, the expiration date had to be advanced as the expiration date was less than eight months away. An official from a vaccine manufacturer said, "As Sanofi distributes vaccines with a short distribution period in Korea, confusion is expected in the vaccine market," adding, "Some analysts say that Sanofi is accelerating the introduction as it has to quickly exhaust its products this year." Sanofi explained that it brought in products produced relatively early so that domestic consumers could receive vaccines quickly. Unlike previous years, influenza strains that will be prevalent in the southern and northern hemispheres this year were consistent, so there was no need for a technical process to change the strain, which allowed the production of vaccines for the northern hemisphere to be accelerated. Imported finished products have more testing processes and are more difficult than domestic companies, so no matter how fast they speed up, the remaining validity period is bound to be shorter than other domestic vaccines that have been released at the same time. An official from Sanofi said, "Korean corporations have tried to advance the timing due to the late introduction schedule of imported products in Korea, and we have secured vaccines as soon as possible as we can produce Northern Hemisphere products early this year due to the same strain." "The introduction process may be complicated and the expiration date may be relatively short, but we did our best to supply the product at a similar time to other vaccines. Also Vaxigrip Tetra whose expiration date is from May to July 2023 is going to be supplied sequentially in Korea," he said.
